SMIM34B

Across TCGA pan-cancer cohorts, SMIM34B RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated SMIM34B data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SMIM34B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMIM34B expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

BLCA, UCEC, and MESO are the cancer types where SMIM34B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	All	0.097	0.626	<.001	99	view →
UCEC	OS	Tertile	II,III,IV	0.133	0.768	<.001	72	view →
MESO	DFS	Tertile	III,IV	0.043	0.415	<.001	54	view →
ESCA	DFS	Tertile	IV	0.826	0.284	.034	36	view →
THYM	DFS	Tertile	II,III,IV	0.123	0.851	<.001	18	view →
OV	OS	Tertile	III,IV	0.639	0.699	.046	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMIM34B–BLCA (DFS)

Open the BLCA breakdown →